Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar
Medtronic, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
This 30-day notice describes a manufacturing process change for Medtronic pacemaker models listed under PMA P010015. The stated change is the introduction of a second Medium Rate (MR) Headers manufacturing line and inspection updates to the MR Headers line currently in production.
The supplement type is a 30-Day Notice, and the supplement reason is a process change involving manufacturer, sterilizer, packager, or supplier. The decision code OK30 indicates the notice was accepted. The source statement reports the intended manufacturing change but does not provide independent proof of safety or clinical effectiveness. Specific details about the inspection updates are absent from the supplied fields.
FDA approval order statement
the introduction of a second Medium Rate (MR) Headers manufacturing line and to make inspection updates to the MR Headers Line that is currently in production
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010015/S591
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- Decision code
- OK30
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Medtronic, Inc.
- Product code
- LWP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010015 · Original PMA
MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM
P010015/S591 received
Application receipt date recorded by FDA.
P010015/S590 · Related supplement
Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P
P010015/S591 · FDA decision
30-Day Notice
P010015/S592 · Related supplement
Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P
Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010015
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Aug 28, 2001 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA approval | Apr 25, 2016 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010015/S591
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

